The AGI Dermatics lead compound is T4N5 Liposome Lotion, known as Dimericine. This drug encapsulates the DNA repair enzyme T4 endonuclease V in a liposome engineered to deliver the enzyme into cells of the skin. Studies in cell cultures and animals indicate T4N5 liposomes increased repair of DNA damage caused by UV. In clinical testing in xeroderma pigmentosum (XP), a genetic disease predisposing to skin cancer, Dimericine reduced the incidence of pre-malignant actinic keratosis and basal cell carcinoma (The Lancet 357:926, 2001).
The drug is currently in clinical testing in the reduction of skin cancer in organ transplant patients, and in patients with a history of skin cancer or pre-malignant skin cancer.
Edit: removed commercial content.
Edited by niner, 31 January 2008 - 03:57 AM.